Cargando…

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism

Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmons, J. G., Manners, R., Bailey, M., McDougall, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357729/
https://www.ncbi.nlm.nih.gov/pubmed/33881757
http://dx.doi.org/10.1007/s42000-021-00292-4
_version_ 1783737191868923904
author Timmons, J. G.
Manners, R.
Bailey, M.
McDougall, C.
author_facet Timmons, J. G.
Manners, R.
Bailey, M.
McDougall, C.
author_sort Timmons, J. G.
collection PubMed
description Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high peri-operative risk. We present an elderly patient with mild hypercalcemia secondary to primary hyperparathyroidism. The clinical decision was initially to watch and wait. The patient subsequently developed cognitive impairment and was diagnosed with mixed Alzheimer’s disease/vascular dementia. She became dependent for all care and housebound. A therapeutic trial of cinacalcet was commenced following a further acute rise in serum calcium. Significant reversal of her functional and cognitive deficit occurred. She was no longer fully dependent. Mini mental state examination (MMSE) improved from 8/30 to 21/30. In vulnerable neural systems, even mild elevation in serum calcium may have a profound effect on cognition and function. We propose a therapeutic trial of cinacalcet in such patients.
format Online
Article
Text
id pubmed-8357729
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83577292021-08-30 Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism Timmons, J. G. Manners, R. Bailey, M. McDougall, C. Hormones (Athens) Teaching Case Presentations Primary hyperparathyroidism (pHPT) is a common endocrine disorder. Often serum calcium is minimally elevated with few symptoms. In elderly patients with multiple co-morbidities, the decision to “watch and wait” is often most clinically appropriate as operative intervention is associated with high peri-operative risk. We present an elderly patient with mild hypercalcemia secondary to primary hyperparathyroidism. The clinical decision was initially to watch and wait. The patient subsequently developed cognitive impairment and was diagnosed with mixed Alzheimer’s disease/vascular dementia. She became dependent for all care and housebound. A therapeutic trial of cinacalcet was commenced following a further acute rise in serum calcium. Significant reversal of her functional and cognitive deficit occurred. She was no longer fully dependent. Mini mental state examination (MMSE) improved from 8/30 to 21/30. In vulnerable neural systems, even mild elevation in serum calcium may have a profound effect on cognition and function. We propose a therapeutic trial of cinacalcet in such patients. Springer International Publishing 2021-04-21 2021 /pmc/articles/PMC8357729/ /pubmed/33881757 http://dx.doi.org/10.1007/s42000-021-00292-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Teaching Case Presentations
Timmons, J. G.
Manners, R.
Bailey, M.
McDougall, C.
Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title_full Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title_fullStr Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title_full_unstemmed Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title_short Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
title_sort cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
topic Teaching Case Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357729/
https://www.ncbi.nlm.nih.gov/pubmed/33881757
http://dx.doi.org/10.1007/s42000-021-00292-4
work_keys_str_mv AT timmonsjg cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism
AT mannersr cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism
AT baileym cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism
AT mcdougallc cognitiveimpairmentreversedbycinacalcetadministrationinprimaryhyperparathyroidism